Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif

PHASE4CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

Betaferon/Betaseron

250ug administrated with Betaject

DRUG

Rebif

44ug administered with Rebiject II

DRUG

Betaferon/Betaseron

250ug administrated with Betaject light

Trial Locations (59)

13006

Marseille

13616

Aix-en-Provence

15000

Aurillac

19100

Brive-la-Gaillarde

27023

Évreux

29000

Quimper

30900

Nîmes

31400

Toulouse

33000

Bordeaux

33505

Libourne

34170

Castelnau-le-Lez

44000

Nantes

44800

Saint-Herblain

50000

Saint Lÿ

54000

Nancy

59140

Dunkirk

62321

Boulogne-sur-Mer

62505

Saint-Omer

66000

Perpignan

70000

Vesoul

72000

Le Mans

74011

Annecy

83500

La Seyne-sur-Mer

94000

Créteil

Unknown

Alkirch

Belfort

Blaye

Brest

Carcassonne

Chamaliÿres

Champigny-sur-Marne

Colmar

Corbeil Essones Cedex

Dijon

Dreux

Elbeuf

Évry

Le Mans

Lille

Lomme

Lyon

Montpellier

Nancy

Nice

Paris

Pau

Poissy

Quimper

Reims

Rennes

Rouen

Rueil-Malmaison

Saint-Etienne

Saint-Quentin

Strasbourg

Tourcoing

Trélazé

Vendôme

Vichy

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY